<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340248</url>
  </required_header>
  <id_info>
    <org_study_id>125HPS11F</org_study_id>
    <nct_id>NCT01340248</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single-dose, crossover clinical trial to evaluate the food effect
      on the pharmacokinetics of Dilatrend SR 64mg capsule after oral administration in healthy
      male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation of pharmacokinetics</measure>
    <time_frame>pre-dose(0h), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48h</time_frame>
    <description>The effect of food on PK after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of safety</measure>
    <time_frame>from screenig to post-study visit</time_frame>
    <description>adverse event monitoring
physical examination, vital sign, ECOG, laboratory test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Stable Angina</condition>
  <arm_group>
    <arm_group_label>Dilatrend 64mg capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Randomized, open-label, single dose, two-period, two-way, crossover study
group : Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet
group : Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dilatrend 64mg capsule</intervention_name>
    <description>Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet
Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting</description>
    <arm_group_label>Dilatrend 64mg capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 20 aged and 50 aged in healthy adults

          -  Weight more than 55kg, IBW 20% within the range

          -  Agreement with written informed consent

        Exclusion Criteria:

          -  Subject has hypersensitivity reaction or clinically significant history about
             investigational drug

          -  Clinically significant cardiovascular system, respiratory system, liver, renal,
             endocrine system, gastrointestinal system, central nervous system, blood tumor, mental
             disease, skin disease and so on

          -  Inadequate result of laboratory test

               -  AST(SGOT) or ALT(SGPT) &gt; 1.5 x upper limit of normal range

          -  Continued to be taking caffeine (caffeine &gt; 5 cup/day), drinking(alcohol &gt; 210 g/day)
             or during clinical trials can not be drunk or severe heavy smoker (cigarette &gt; 10
             cigarettes per day)

          -  Creatinine clearance &lt; 80ml/min

          -  Subject with known for history(such as gastrointestinal disease or operation) with
             affect the absorption of drug

          -  Subject takes an abnormal meal which affect the ADME of drug

          -  Previously participated in other trial within 90 days

          -  Previously make whole blood donation within 60 days or component blood donation within
             30 days

          -  Subject with positive reaction for reason of laboratory test result

          -  An impossible one who participates in clinical trial by investigator's decision
             including for reason of laboratory test result
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyungpook national university</name>
      <address>
        <city>Daegu</city>
        <state>Seoul</state>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2011</study_first_posted>
  <last_update_submitted>December 20, 2011</last_update_submitted>
  <last_update_submitted_qc>December 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chong Kun Dang Pharmaceutical</name_title>
    <organization>Cho, Jung Ah/CRA</organization>
  </responsible_party>
  <keyword>food effect</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>healthy male volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

